Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Shock. 2014 Jul;42(1):52–59. doi: 10.1097/SHK.0000000000000169

Figure 2. Itraconazole decreased expression and altered the electrophoretic mobility of Fcγ receptors.

Figure 2

J774.1 Cells (∼1 × 106) were treated for 16 h at 37°C with ICZ (1 μM) or vehicle control (DMSO). A and B, cell surface and C and D, total cellular expression of FcγI and FcγIII/II receptors was determined by flow cytometry using APC-labeled anti-mouse CD64 and FITC-labeled rat anti-mouse CD16/CD32 antibodies. E, ICZ altered the electrophoretic mobility of FcγIII/II receptors. At the end of the incubation period with either ICZ or DMSO, cells were lysed, equal amounts of protein for each sample (50 μg) were resolved by SDS-PAGE, and the presence of FcγRIII/II was determined by Western blotting. F, mRNA levels of FcγRI: Fcgr1 (CD64), FcγRII: Fcgr2b (CD32), FcγRIII: Fcgr3 (CD16) were determined using qRT-PCR. Values were determined using a standard curve and expressed as copy number. All values were normalized to GAPDH mRNA levels. Results from three independent experiments performed in triplicate for each sample were used to calculate the mean and standard error depicted. Statistical analysis was performed using ANOVA. * P ≤ 0.05 compared to Control (DMSO).